CL2019001717A1 - Anticuerpos contra el lif y usos de los mismos. - Google Patents

Anticuerpos contra el lif y usos de los mismos.

Info

Publication number
CL2019001717A1
CL2019001717A1 CL2019001717A CL2019001717A CL2019001717A1 CL 2019001717 A1 CL2019001717 A1 CL 2019001717A1 CL 2019001717 A CL2019001717 A CL 2019001717A CL 2019001717 A CL2019001717 A CL 2019001717A CL 2019001717 A1 CL2019001717 A1 CL 2019001717A1
Authority
CL
Chile
Prior art keywords
antibodies against
lif
against lif
antibodies
describes
Prior art date
Application number
CL2019001717A
Other languages
English (en)
Spanish (es)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Johan Fransson
Jean-Philippe Julien
Swetha Raman
Original Assignee
Mosaic Biomedicals S L U
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaic Biomedicals S L U, Fundacio Privada Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncologica De Vall Hebron filed Critical Mosaic Biomedicals S L U
Publication of CL2019001717A1 publication Critical patent/CL2019001717A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2019001717A 2016-12-19 2019-06-19 Anticuerpos contra el lif y usos de los mismos. CL2019001717A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13

Publications (1)

Publication Number Publication Date
CL2019001717A1 true CL2019001717A1 (es) 2020-02-28

Family

ID=67138942

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001717A CL2019001717A1 (es) 2016-12-19 2019-06-19 Anticuerpos contra el lif y usos de los mismos.
CL2021000950A CL2021000950A1 (es) 2016-12-19 2021-04-16 Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021000950A CL2021000950A1 (es) 2016-12-19 2021-04-16 Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717)

Country Status (23)

Country Link
US (2) US11390670B2 (https=)
EP (2) EP3555132B1 (https=)
JP (3) JP7100056B2 (https=)
KR (3) KR102716931B1 (https=)
CN (2) CN111868086B (https=)
AU (1) AU2017381585B2 (https=)
BR (1) BR112019012691A2 (https=)
CA (1) CA3047528A1 (https=)
CL (2) CL2019001717A1 (https=)
DK (1) DK3555132T3 (https=)
ES (1) ES2971126T3 (https=)
FI (1) FI3555132T3 (https=)
HR (1) HRP20240195T8 (https=)
HU (1) HUE065241T2 (https=)
IL (2) IL294088B2 (https=)
LT (1) LT3555132T (https=)
MX (2) MX2019007376A (https=)
PL (1) PL3555132T3 (https=)
RS (1) RS65187B1 (https=)
SA (1) SA519402119B1 (https=)
SI (1) SI3555132T1 (https=)
SM (1) SMT202400065T1 (https=)
ZA (1) ZA201904533B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017381585B2 (en) * 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
WO2019197903A1 (en) * 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
TWI841810B (zh) 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
JP7691668B2 (ja) 2020-12-31 2025-06-12 諾納生物（蘇州）有限公司 ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用
AU2022273303A1 (en) * 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DE69635630T2 (de) 1995-04-24 2006-08-10 Genentech, Inc., South San Francisco Verwendung eines Leukämie-hemmenden Faktor Antagonisten
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2010505876A (ja) 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
JP6488520B2 (ja) 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
US20160237158A1 (en) 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
US10808026B2 (en) 2013-10-09 2020-10-20 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
TWI486172B (zh) 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
WO2016040657A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
AU2017381585B2 (en) * 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
WO2019197903A1 (en) * 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
CN112703202A (zh) * 2018-06-18 2021-04-23 免疫医疗有限公司 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法

Also Published As

Publication number Publication date
BR112019012691A2 (pt) 2019-11-19
AU2017381585A1 (en) 2019-07-18
KR102599557B1 (ko) 2023-11-07
CN118652335A (zh) 2024-09-17
EP4321219A2 (en) 2024-02-14
RS65187B1 (sr) 2024-03-29
KR102716931B1 (ko) 2024-10-15
IL294088B1 (en) 2023-06-01
SI3555132T1 (sl) 2024-04-30
JP2020512388A (ja) 2020-04-23
IL294088B2 (en) 2023-10-01
IL294088A (en) 2022-08-01
CL2021000950A1 (es) 2021-11-26
SA519402119B1 (ar) 2023-02-19
KR20240149987A (ko) 2024-10-15
LT3555132T (lt) 2024-02-26
FI3555132T3 (fi) 2024-02-08
MX2019007376A (es) 2020-02-07
KR102784394B1 (ko) 2025-03-19
JP2022130632A (ja) 2022-09-06
HRP20240195T8 (hr) 2024-05-24
AU2017381585B2 (en) 2025-02-13
EP4321219A3 (en) 2024-05-15
US11390670B2 (en) 2022-07-19
US20190352389A1 (en) 2019-11-21
EP3555132B1 (en) 2023-11-15
KR20230125099A (ko) 2023-08-28
JP7100056B2 (ja) 2022-07-12
PL3555132T3 (pl) 2024-04-22
ES2971126T3 (es) 2024-06-03
IL267450A (en) 2019-08-29
JP2024075682A (ja) 2024-06-04
CN111868086B (zh) 2024-07-16
MX2024003178A (es) 2024-03-25
EP3555132A1 (en) 2019-10-23
HRP20240195T1 (hr) 2024-04-26
JP7459173B2 (ja) 2024-04-01
CN111868086A (zh) 2020-10-30
SMT202400065T1 (it) 2024-03-13
NZ755004A (en) 2025-08-29
KR20190122652A (ko) 2019-10-30
ZA201904533B (en) 2024-08-28
IL267450B (en) 2022-07-01
CA3047528A1 (en) 2018-06-28
HUE065241T2 (hu) 2024-05-28
DK3555132T3 (da) 2024-02-05
US20230042095A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
CL2019001717A1 (es) Anticuerpos contra el lif y usos de los mismos.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2019002461A1 (es) Arn terapéutico.
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
ECSP17073743A (es) Moduladores de k-ras
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX2018003491A (es) Represores de htt y usos de estos.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
DOP2018000005A (es) Compuestos inhibidores de la señalización de la vía de notch
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CO2021007444A2 (es) Anticuerpos antiperiostina y usos de estos
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.